REQUEST A REP
Getting-started Water_Subpage_Background_small_1

Chiesi Total CareSM and Patient Support

Comprehensive Support and Services for Healthcare Providers and Patients

A single call to your dedicated Chiesi Total Care team is all it takes, and they will guide you through the process of getting a patient started on MYCAPSSA therapy. The Chiesi Total Care program provides assistance to patients with or without commercial insurance, Medicaid, and Medicare.*

*Please refer to the full Terms and Conditions for additional eligibility requirements.

Patients May Pay as Little as $0 for Their MYCAPSSA Prescription

To be eligible for these programs:
  • Patient must be enrolled in Chiesi Total Care. (Enrollment and Authorization Form will be mailed to your patient’s home)
  • Patient must have commercial insurance and a valid prescription for a US FDA-approved indication for MYCAPSSA
  • Patient must be a resident of the United States or one of its territories

outofpocket outofpocket-mobile
smartphone-icon
For information about all the supporting services available to you and your patients, contact Chiesi Total Care.
chiesitotalcare.com 1-833-346-2277
Watch Jim as he talks about his experience with Chiesi Total Care.
Jim thumbnail
Chiesi Global Rare Diseases: Our Commitment
Chiesi Global Rare Diseases is committed to helping address wellness within the rare disease community
We strive to provide comprehensive support in the lives of people living with rare diseases. We work in close partnership with caregivers, patient communities, healthcare professionals, government authorities, and other stakeholders to help make an impact in the rare disease community. We relentlessly pursue sustainable development goals with passion, courage, teamwork, and innovation. We believe—from timely and accurate diagnoses to receiving treatments and finding supportive communities—that no one should feel alone.
Jim, MYCAPSSA patient
jim-image
Let’s Connect
Get in touch with a MYCAPSSA Sales Representative.
REQUEST A REP

Important Safety Information

Contraindications

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.


Warnings and Precautions

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

New onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with MYCAPSSA and other somatostatin analogs. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.


Adverse Reactions

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.


Drug Interactions

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.


Pregnancy

Advise premenopausal females of the potential for an unintended pregnancy.

Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information, including Medication Guide
.

Indication

Indication and usage

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Important Safety Information

Contraindications

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.


Warnings and Precautions

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

New onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with MYCAPSSA and other somatostatin analogs. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.


Adverse Reactions

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.


Drug Interactions

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.


Pregnancy

Advise premenopausal females of the potential for an unintended pregnancy.

Please report adverse events to Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Full Prescribing Information, including Medication Guide
.

Indication

Indication and usage

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.